Literature DB >> 8642636

Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.

A M Caliendo1, A Savara, D An, K DeVore, J C Kaplan, R T D'Aquila.   

Abstract

Certain amino acid substitutions in the reverse transcriptase (RT), including D67N, K70R, T215Y, and K219Q, cause high-level resistance of human immunodeficiency virus type 1 (HIV-1) to zidovudine (3'-azidothymidine; AZT) and appear to approximate the template strand of the enzyme-template-primer complex in structural models. We studied whether this set of mutations altered RT-template-primer interaction as well as their effect on virus replication in the absence of inhibitor. When in vitro polymerization was limited to a single association of an RT with an oligodeoxynucleotide-primed heteropolymeric RNA template (a single processive cycle), recombinant-expressed mutant 67/70/215/219 RT synthesized 5- to 10-fold more high-molecular-weight DNA products (>200 nucleotides in length) than wild-type RT. This advantage was maintained as deoxynucleoside triphosphate (dNTP) concentrations were decreased to limiting levels. In contrast, no difference was seen between wild-type and mutant RTs under conditions allowing repeated associations of enzyme with template-primer. Because intracellular dNTP concentrations are low prior to mitogenic stimulation, we compared replication of mutant 67/70/215/219 virus and wild-type virus in peripheral blood mononuclear cells (PBMC) stimulated before and after infection. In the absence of inhibitor, mutant 67/70/215/219 virus had a replication advantage in PBMC stimulated with phytohemagglutinin and interleukin-2 after infection, but virus replication was similar in PBMC stimulated before infection in vitro. The results confirm that RT mutations D67N, K70R, T215Y, and K219Q affect an enzyme-template-primer interaction in vitro and suggest that such substitutions may affect HIV-1 pathogenesis during therapy by increasing viral replication capacity in cells stimulated after infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642636      PMCID: PMC190052     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Complete nucleotide sequences of functional clones of the AIDS virus.

Authors:  L Ratner; A Fisher; L L Jagodzinski; H Mitsuya; R S Liou; R C Gallo; F Wong-Staal
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

2.  Studies on the mechanism of human immunodeficiency virus reverse transcriptase. Steady-state kinetics, processivity, and polynucleotide inhibition.

Authors:  C Majumdar; J Abbotts; S Broder; S H Wilson
Journal:  J Biol Chem       Date:  1988-10-25       Impact factor: 5.157

3.  Human immunodeficiency virus 1 reverse transcriptase. Template binding, processivity, strand displacement synthesis, and template switching.

Authors:  H E Huber; J M McCoy; J S Seehra; C C Richardson
Journal:  J Biol Chem       Date:  1989-03-15       Impact factor: 5.157

4.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

5.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

6.  HIV-1 reverse transcriptase/ribonuclease H: high level expression in Escherichia coli from a plasmid constructed using the polymerase chain reaction.

Authors:  R T D'Aquila; W C Summers
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

7.  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

Authors:  J A Zack; S J Arrigo; S R Weitsman; A S Go; A Haislip; I S Chen
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

8.  Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells.

Authors:  T Shirasaka; S Chokekijchai; A Yamada; G Gosselin; J L Imbach; H Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

9.  Rapid and sensitive viral culture method for human immunodeficiency virus type 1.

Authors:  J B Jackson; R W Coombs; K Sannerud; F S Rhame; H H Balfour
Journal:  J Clin Microbiol       Date:  1988-07       Impact factor: 5.948

10.  HIV-1 replication is controlled at the level of T cell activation and proviral integration.

Authors:  M Stevenson; T L Stanwick; M P Dempsey; C A Lamonica
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

View more
  35 in total

1.  Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 2.  A fossil record of zidovudine resistance in transmitted isolates of HIV-1.

Authors:  D R Kuritzkes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

3.  Antiretroviral Drug Resistance in HIV-1.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

Review 4.  Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  Dan Turner; Bluma Brenner; Mark A Wainberg
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

5.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

6.  In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.

Authors:  Masanori Kobayashi; Tomokazu Yoshinaga; Takahiro Seki; Chiaki Wakasa-Morimoto; Kevin W Brown; Robert Ferris; Scott A Foster; Richard J Hazen; Shigeru Miki; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

7.  Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.

Authors:  Francine Bouchonnet; Elisabeth Dam; Fabrizio Mammano; Vaea de Soultrait; Gaëlle Henneré; Henri Benech; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

8.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

9.  L74V increases the reverse transcriptase content of HIV-1 virions with non-nucleoside reverse transcriptase drug-resistant mutations L100I+K103N and K101E+G190S, which results in increased fitness.

Authors:  Jiong Wang; Dongge Li; Robert A Bambara; Hongmei Yang; Carrie Dykes
Journal:  J Gen Virol       Date:  2013-03-27       Impact factor: 3.891

10.  Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.

Authors:  G Bleiber; M Munoz; A Ciuffi; P Meylan; A Telenti
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.